Dynacure names Chris Freitag (MD)…
Strasbourge (France)July 10, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the expansion of its leadership team with the appointment of Chris Freitag (MD) as Chief Medical Officer. He will be responsible for the company’s medical strategy, clinical operations and expand Dynacure’s network with medical and academic organizations. “I’m e
READ MOREDynacure secures €47 million financing…
Strasbourge (France)July 6, 2018Financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs forotherorphan disorders Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance
READ MOREBelinda Cowling (PhD) joins Dynacure…
Strasbourg (France)April 30, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today that Belinda Cowling (PhD) has joined the management team as Head of Research. Dynacure’s first drug discovery program focuses on centronuclear myopathies (CNM), a rare debilitating disease affecting children and young adults, through the use of an antisense oligonu
READ MOREIonis licenses novel antisense drug…
Carlsbad, Calif. and Strasbourg, FranceNovember 9, 2017Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the pro
READ MOREDynacure joins ongoing Natural History…
Strasbourg (France)September 26, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. Dynac
READ MOREDynacure appoints its Management Team…
Strasbourg (France)March 9, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The
READ MOREKurma Partners and Idinvest Partners…
ParisOctober 24, 2016Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. Dynacure is a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. “The
READ MORE